Brief: Genevant Sciences And Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
03/03/2026 21:20
March 3 (Reuters) - Arbutus Biopharma Corp ABUS.O: GENEVANT SCIENCES AND ARBUTUS BIOPHARMA ANNOUNCE $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA ROIVANT SCIENCES - ARBUTUS IS CURRENTLY EVALUATING A RETURN OF CAPITAL TO SHAREHOLDERS FOR Q3 OF CALENDAR YEAR 2026 Source text: ID:nGNX7ZNTnK Further company coverage: ABUS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple